 | What Analysts Are Recommending for GILD and ABBV in February
finance.yahoo.com - February 21 at 3:13 PM |
| GILD or ABBV: Which Is Expected to Report Faster EPS Growth?
finance.yahoo.com - February 21 at 3:13 PM |
 | 2 Frustrating Flops, Plus Welcome to the Wrinkle Wars
www.fool.com - February 21 at 10:16 AM |
 | Insider Selling: Gilead Sciences, Inc. (GILD) Director Sells 19,068 Shares of Stock
www.americanbankingnews.com - February 20 at 8:16 PM |
| Biotech Stock Roundup: ICPT Strong on NASH Drug Data, Collaborations & More
finance.yahoo.com - February 20 at 3:10 PM |
 | Global Human Immunodeficiency Virus (HIV) Drugs Market 2019-2025 with AbbVie, Merck, Gilead Sciences, Bristol-Myers Squibb, Janssen & GSK Dominating
www.prnewswire.com - February 20 at 11:20 AM |
 | Can Gilead Recover After Latest Earnings Downfall?
seekingalpha.com - February 20 at 5:11 AM |
| Gilead's Recent NASH Trial Failure Represents Opportunity For Galectin
seekingalpha.com - February 20 at 5:11 AM |
| Gilead Receives Approval in Canada for YESCARTA™ (Axicabtagene Ciloleucel) CAR T Therapy for Adults With Relapsed or Refractory Large B-cell Lymphoma After Two or More Lines of Systemic Therapy
finance.yahoo.com - February 19 at 3:14 PM |
| Intercept Shares Soar To Multimonth High After NASH Drug Aces Late-Stage Trial
finance.yahoo.com - February 19 at 3:14 PM |
| Intercept Comes in First With Liver Drug, But Race Isn’t Over
finance.yahoo.com - February 19 at 3:14 PM |
| After Gilead Failed, Intercept Stock Rises On NASH Treatment Study
finance.yahoo.com - February 19 at 3:14 PM |
| Gilead Sciences (GILD) versus Avrobio (AVRO) Critical Contrast
www.americanbankingnews.com - February 17 at 1:16 AM |
| U.S. Medicare plans to track CAR-T cancer therapy outcomes
finance.yahoo.com - February 15 at 3:10 PM |
| Gilead Could Be The Winner From Washington State's Winner-Take-All Hep C Proposal
seekingalpha.com - February 15 at 5:09 AM |
| Gilead: What Just Happened?
seekingalpha.com - February 15 at 5:09 AM |
| Despite M&A Spree, Biotech ETFs Slide on Mixed Earnings
finance.yahoo.com - February 14 at 3:09 PM |
| $5.33 Billion in Sales Expected for Gilead Sciences, Inc. (GILD) This Quarter
www.americanbankingnews.com - February 14 at 6:48 AM |
 | Biotech Stock Roundup: Regeneron Impresses in Q4, Gilead Slumps, MacroGenics Soars
www.zacks.com - February 13 at 3:15 PM |
| Gilead's (GILD) Late-Stage Study on Liver Disease Drug Fails
finance.yahoo.com - February 13 at 5:11 AM |
| Dash for NASH trips up Gilead, but 'fatty liver disease' remains biotech target
finance.yahoo.com - February 13 at 5:10 AM |
 | Notable Tuesday Option Activity: EA, GILD, NKE
www.nasdaq.com - February 12 at 3:06 PM |
 | Why Gilead’s Pain Is Intercept’s Gain
247wallst.com - February 12 at 3:06 PM |
| Gilead Sciences: Reaching An Inflection Point
seekingalpha.com - February 12 at 3:06 PM |
| Gilead's Liver-Drug Setback Clouds $35 Billion Dream
finance.yahoo.com - February 12 at 3:06 PM |
| Gilead's Failed NASH Drug Trial Drags Stock Lower
finance.yahoo.com - February 12 at 3:06 PM |
| Gilead Sciences Stock Tumbles After Being Hit With Disappointing Trial Data
finance.yahoo.com - February 12 at 3:06 PM |
| Viking Therapeutics Breaks Out After Gilead's Clinical Failure
finance.yahoo.com - February 12 at 3:06 PM |
| Gilead Flops In Liver Disease — Does Its Second Shot Have A Chance?
finance.yahoo.com - February 12 at 3:06 PM |
| Gilead Sciences Falls on Failed Cirrhosis Drug Trial of Selonsertib
finance.yahoo.com - February 12 at 3:06 PM |
| Here's Why Viking Therapeutics Rose as Much as 13.9% Today
finance.yahoo.com - February 12 at 3:06 PM |
 | Gilead Sciences Stock Slides Lower on NASH Drug Failure
investorplace.com - February 12 at 1:36 PM |
| Citigroup Lowers Gilead Sciences (GILD) to Neutral
www.americanbankingnews.com - February 12 at 12:13 PM |
| Raymond James Trims Gilead Sciences (GILD) Target Price to $85.00
www.americanbankingnews.com - February 12 at 12:08 PM |
| Gilead Sciences, Inc. (GILD) Expected to Announce Earnings of $1.62 Per Share
www.americanbankingnews.com - February 12 at 7:12 AM |
 | Gilead stock down nearly 4% as drug trial fizzles
www.marketwatch.com - February 12 at 5:04 AM |
| Gilead's selonsertib flunks late-stage NASH study
seekingalpha.com - February 12 at 5:04 AM |
| Gilead Announces Topline Data From Phase 3 STELLAR-4 Study of Selonsertib in Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)
finance.yahoo.com - February 12 at 5:04 AM |
| Short Interest in Gilead Sciences, Inc. (GILD) Declines By 14.0%
www.americanbankingnews.com - February 12 at 3:40 AM |
| Wells Fargo & Co Downgrades Gilead Sciences (GILD) to Market Perform
www.americanbankingnews.com - February 11 at 8:40 PM |
| [$$] Big Pharma’s Big Cancer Hope Is Fizzling
finance.yahoo.com - February 10 at 8:11 PM |
| Why Gilead Sciences Stock Perked Up in January
www.fool.com - February 10 at 12:12 PM |
| Why Agenus Inc. Stock Took Flight in January
finance.yahoo.com - February 8 at 3:04 PM |
| Q1 2019 EPS Estimates for Gilead Sciences, Inc. (GILD) Cut by Analyst
www.americanbankingnews.com - February 8 at 7:10 AM |
| Gilead Sciences, Inc. Expected to Post Q1 2019 Earnings of $1.43 Per Share (GILD)
www.americanbankingnews.com - February 8 at 7:10 AM |
| Gilead Sciences, Inc. Forecasted to Post Q1 2019 Earnings of $1.56 Per Share (GILD)
www.americanbankingnews.com - February 8 at 7:10 AM |
| Svb Leerink Brokers Reduce Earnings Estimates for Gilead Sciences, Inc. (GILD)
www.americanbankingnews.com - February 7 at 8:08 AM |
| Gilead: What A Difference An O'Day Can Make
seekingalpha.com - February 7 at 5:07 AM |
| 4 New CEOs to Watch in 2019
finance.yahoo.com - February 6 at 3:14 PM |
| Analysts Focus On Gilead's Late-Stage Data Readouts Following Mixed Q4
finance.yahoo.com - February 6 at 5:18 AM |
